The US Food and Drug Administration (FDA) is requiring Pfizer/BioNTech and Moderna to update their Covid-19 vaccine warning labels, expanding information about the rare risk of heart inflammation following vaccination. The move aims to provide greater transparency about myocarditis and pericarditis, which, while rare, have been observed after mRNA Covid-19 shots in certain age groups.
Previously, vaccine labels included warnings about these heart-related risks, especially for young males. Now, the FDA is broadening the warning to specifically address males ages 16 to 25, after health insurance data revealed increased rates of myocarditis and pericarditis in this group within seven days of vaccination. Among males in this age range, about 38 cases were reported per million doses, compared to an overall rate of eight cases per million across people ages 6 months to 64 years.
Health officials emphasize that the risk of heart inflammation remains rare and typically resolves quickly. The Centers for Disease Control and Prevention (CDC) reports that, in most cases, myocarditis following vaccination is mild and short-lived. The CDC also notes that Covid-19 infection itself carries a higher risk of myocarditis or pericarditis than the vaccines do.
According to the FDA, the update is part of a commitment to “radical transparency.” A spokesperson for the Department of Health and Human Services stated that the new labeling is intended to ensure that vaccine recipients are fully informed. Neither Pfizer nor Moderna responded to requests for comment.
The FDA’s decision follows a review of data from millions of vaccine doses administered since 2020. While some critics, including Health and Human Services Secretary Robert F. Kennedy Jr. and Senator Ron Johnson, have questioned vaccine safety or the timeliness of risk disclosure, health experts maintain that the US vaccine safety monitoring system has worked as intended—quickly updating guidance and clinical recommendations as new information emerges.
The agency is also shifting its approach to booster approval, announcing this week that updated Covid-19 shots may be limited to adults 65 and older and people at high risk for severe disease. Officials want more placebo-controlled data for younger, healthy individuals before recommending additional boosters.
The FDA’s advisory committee will meet to discuss strain selection for the next round of Covid-19 vaccines, expected to become available this fall. Meanwhile, health authorities continue to monitor vaccine effectiveness and safety data to guide their recommendations for the public.
